Business Advisory Board

ADDF draws the reviewers for its grant selection from two different bodies: the Scientific Review Board and the Business Advisory Board. The Scientific Review Board is composed of over 150 scientists who encompass various areas of expertise within AD research and also include scientists overseas. The Business Advisory Board comprises members from various backgrounds, including venture capital and the biotechnology and pharmaceutical industry.

Thomas Cirrito, PhD
Stemline Therapeutics, Inc.
Long Island City, NY
John K. Clarke
Cardinal Partners
Princeton, NJ
Mark A. Cochran, PhD
Biotechnology Business Development
Charlottesville, VA
Steven G. Dickman
CBT Advisors
Cambridge, MA
Steven Dyson
Apax Partners, Ltd.
London, England
Julie Eskay-Eagle
September Ventures LLC
Armonk, NY
Stephen M. Goodman, Esq.
Pryor Cashman Sherman & Flynn, LLP
New York, NY
Allan Green, MD, PhD, JD
Allan M. Green Esq., LLC
Cambridge, MA
Elaine Jones, PhD
EuclidSR Partners
New York, NY

Perry Karsen
Celgene Corporation
Summit, NJ

Glenn J. Kline
Academy Funds
Research Triangle Park, NC

Larry Kunstadt, PhD
National Securities Corp
New York, NY
Emer Leahy, PhD
Psychogenics Inc.
Hawthorne, NY
Michael Lefenfeld
SiGNa Chemeistry, Inc.
New York, NY
David Lowe, PhD
PsychoGenics, Inc.
Tarrytown, NY
Michael Lytton, PhD
Oxford Bioscience Partners
Boston, MA
Brian McCarthy, PhD
Influmedix, Inc.
Radnor, PA
Ian Mehr, PhD
Golden Pine Ventures, LLC
Durham, NC
Daniel J. O’Connell
NeuroVentures Capital, LLC
Charlottesville, VA
William Paiva
Chisholm Private Capital
Tulsa, OK
Michael Parker
BIONEST Partners
New York, NY
Debra Peattie, PhD
Valeo Medical Inc.
Concord, MA
Cathrin Petty
Apax Partners & Co.
London, England
Cheryl V. Reicin, PhD
Torys
Toronto, Ontario, Canada
Beth Seidenberg, MD
Kleiner Perkins Caufield & Byers
Menlo Park, CA
David W. Summa
Technology Pathfinders, LLC
Hillsborough, CA
Katya Tsaloun, PhD
Apredica
Watertown, MA

1 out of 3 individuals will be affected by Alzheimer's Disease by the age of 80.

Donate Now

We're doing whatever it takes to find a cure for Alzheimer's Disease. But we can't do it without you. Please give generously today. Learn More

Apply for a Grant

ADDF invites scientists to apply for a grant through its Novel Approaches to Drug Discovery for Alzheimer's Disease research award program. Learn More